Iressa Follow-up trial

Study identifier:1839IL/0555

ClinicalTrials.gov identifier:NCT00357734

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Multicenter open-label, long-term safety trial of treatment extension with ZD1839 in patients who have been treated in other ZD1839 clinical trials.

Medical condition

lung cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Gefitinib

Sex

All

Actual Enrollment

14

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 01 Jan 2005
Primary Completion Date: 01 May 2015
Study Completion Date: 01 May 2015

Study design

Allocation: N/A
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria